Cargando…

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile

BACKGROUND: Clostridioides difficile is the most common cause of antimicrobial-associated diarrhoea in high-income countries. Fluoroquinolone resistance enabled the emergence and intercontinental spread of the epidemic ribotype (RT) 027 strain of C. difficile in the early 2000s. Despite frequent ina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collins, Deirdre A, Wu, Yuan, Tateda, Kazuhiro, Kim, Hee-Jung, Vickers, Richard J, Riley, Thomas V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953319/ https://www.ncbi.nlm.nih.gov/pubmed/33351917 http://dx.doi.org/10.1093/jac/dkaa522

Ejemplares similares

Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile
por: Collins, Deirdre A, et al.
Publicado: (2022)

Ridinilazole: a novel antimicrobial for Clostridium difficile infection
por: Cho, Jonathan C., et al.
Publicado: (2019)

Clostridioides difficile infection in the Asia-Pacific region
por: Collins, Deirdre A., et al.
Publicado: (2019)

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
por: Qian, Xi, et al.
Publicado: (2020)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021
por: Snydman, D. R., et al.
Publicado: (2023)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
por: Thorpe, Cheleste M., et al.
Publicado: (2018)

Genomic characterization of nine Clostridioides difficile strains isolated from Korean patients with Clostridioides difficile infection
por: Ahn, Seung Woo, et al.
Publicado: (2021)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
por: Duperchy, Esther, et al.
Publicado: (2018)

Antimicrobial Susceptibility and Molecular Characterization Using Whole-Genome Sequencing of Clostridioides difficile Collected in 82 Hospitals in Japan between 2014 and 2016
por: Aoki, Kotaro, et al.
Publicado: (2019)

2387. Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
por: Vickers, Richard, et al.
Publicado: (2018)

668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN)
por: Paul, Sumita, et al.
Publicado: (2019)

Evolutionary and Genomic Insights into Clostridioides difficile Sequence Type 11: a Diverse Zoonotic and Antimicrobial-Resistant Lineage of Global One Health Importance
por: Knight, Daniel R., et al.
Publicado: (2019)

1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
por: Duperchy, Esther, et al.
Publicado: (2018)

740. Elucidation of the Mode of Clostridioides difficile Transmission Based on One Health Approach
por: Yoshizawa, Sadako, et al.
Publicado: (2021)

Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017
por: Imwattana, Korakrit, et al.
Publicado: (2022)

Epidemiology of Clostridioides difficile in South Africa
por: de Jager, Pieter, et al.
Publicado: (2021)

A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile
por: Imwattana, Korakrit, et al.
Publicado: (2021)

Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western Australia
por: Knight, Daniel R., et al.
Publicado: (2023)

Antimicrobial Resistance Patterns in Clostridioides difficile Strains Isolated from Neonates in Germany
por: Tilkorn, Friederike K. M. T., et al.
Publicado: (2020)

1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Editorial: Microbial interactions of Clostridioides difficile
por: Goh, Shan, et al.
Publicado: (2023)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
por: Vickers, Richard J, et al.
Publicado: (2017)

Clostridioides difficile Infection in a Japanese Tertiary Children’s Hospital
por: Meguro, Mariko, et al.
Publicado: (2022)

Factors and Conditions That Impact Electroporation of Clostridioides difficile Strains
por: Bhattacharjee, Disha, et al.
Publicado: (2020)

Proteomic Adaptation of Clostridioides difficile to Treatment with the Antimicrobial Peptide Nisin
por: Maaß, Sandra, et al.
Publicado: (2021)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

Iron Effects on Clostridioides difficile Toxin Production and Antimicrobial Susceptibilities
por: Yamaki, Jason, et al.
Publicado: (2022)

Characteristics of Faecal Microbiota in Korean Patients with Clostridioides difficile-associated Diarrhea
por: Jeon, Yong Duk, et al.
Publicado: (2019)

Clostridioides difficile in South American Camelids in Germany: First Insights into Molecular and Genetic Characteristics and Antimicrobial Resistance
por: Dost, Ines, et al.
Publicado: (2023)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Interprofessional Antimicrobial Stewardship Influencing Clostridioides difficile Infection: An 8-Year Study Using Antimicrobial Use Density
por: Yoshida, Junichi, et al.
Publicado: (2019)

92180 Prevalence of Clostridioides difficile strains found in Texas soil
por: Zeidan, Amina R., et al.
Publicado: (2021)

Binding of the extracellular matrix laminin-1 to Clostridioides difficile strains
por: Santos, Mayara Gil de Castro, et al.
Publicado: (2022)

Clostridioides difficile strain-dependent and strain-independent adaptations to a microaerobic environment
por: Weiss, Andy, et al.
Publicado: (2021)

Clostridioides difficile infection and One Health: an equine perspective
por: Hain‐Saunders, Natasza M.R., et al.
Publicado: (2022)

2397. Effects of antimicrobial surgical prophylaxis on rates of Clostridioides difficile infection
por: Hayes, Sarah K, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t7t0agoiffhjlmjjh4hrc4o6q6